Do stellate neurons express unique α7 nicotinic receptor subtypes that could enable cell-type selective targeting?

PARTIALLY ADDRESSED

The debate proposed α7-containing heteromers (α7β2) might be enriched in stellate neurons but provided no evidence. This is critical since previous broad α7 targeting failed in clinical trials, making selectivity essential for therapeutic success. Source: Debate session sess_sda-2026-04-01-gap-004 (Analysis: sda-2026-04-01-gap-004)

Priority: 0.90 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: Do stellate neurons express unique α7 nicotinic receptor subtypes that could enable cell-type selective targeting? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Do stellate neurons express unique α7 nicotinic receptor subtypes that could enable cell-type selective targeting? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

60%

Resolution

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed

✏ update on knowledge_gap by None 2026-04-21T14:21

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps